Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Ocrevus
|
| gptkbp:chemicalFormula |
C646H1008N178O198S4
|
| gptkbp:clinicalTrials |
2010s
autoimmune diseases Phase III every 6 months OPERA I OPERA II ORATORIO recommended_for_MS_treatment. |
| gptkbp:community_service |
available
|
| gptkbp:contraindication |
liver enzyme elevation
active infections neutropenia hypersensitivity reactions hypersensitivity to ocrelizumab |
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:dosageForm |
solution for infusion
|
| gptkbp:drugInterdiction |
none significant
long half-life immunosuppressive effects |
| gptkbp:firstAwarded |
multiple sclerosis
|
| gptkbp:formulation |
sterile liquid
|
| gptkbp:hasPopulation |
adults
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ocrelizumab
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
2017
|
| gptkbp:launchSite |
vein
|
| gptkbp:mandates |
relapsing forms of multiple sclerosis
primary progressive multiple sclerosis |
| gptkbp:marketedAs |
gptkb:European_Union
gptkb:United_States |
| gptkbp:offers |
high
|
| gptkbp:patentStatus |
patented
|
| gptkbp:regulatoryCompliance |
2017
|
| gptkbp:releaseYear |
2000s
|
| gptkbp:research |
public and private sectors
|
| gptkbp:research_areas |
immunomodulator
|
| gptkbp:researchAreas |
neurology
|
| gptkbp:route |
IV
|
| gptkbp:safetyFeatures |
post-marketing surveillance
|
| gptkbp:sells |
gptkb:Ocrevus
|
| gptkbp:servesLine |
none
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
increased risk of infections
infusion reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
CD20 protein
|
| gptkbp:triggerType |
B-cell depletion
|
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:weight |
146 kDa
|